Meaning
ACS
ACUTE CORONARY SYNDROME
These findings suggest that rivaroxaban-5 mg twice daily may be a reasonable alternative to enoxaparin in the acute phase of ACS, which may provide useful information for designing future definitive randomized clinical trials with sufficient sample sizes.This randomized equivalence and noninferiority trial compares safety and efficacy of enoxaparin vs rivaroxaban 2.5 or 5 mg for patients with acute coronary syndrome (ACS) in the acute phase.